Study of LAU-7b for the Treatment of Long COVID in Adults

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

August 5, 2024

Study Completion Date

November 30, 2024

Conditions
Long COVID
Interventions
DRUG

LAU-7b for 3 cycles

Three cycles of 14 days of once-a-day intake of LAU-7b, each followed by a treatment intake pause of14 days.

DRUG

LAU-7b for 1 cycle, then placebo

One cycle of 14 days of once-a-day intake of LAU-7b followed by two cycles of 14 days of placebo administered similarly, each followed by a treatment intake pause of14 days.

OTHER

Placebo for 3 cycles

Three cycles of 14 days of once-a-day intake of placebo, each followed by a treatment intake pause of14 days

Trial Locations (5)

G7H 5H6

CIUSS du Saguenay-Lac-St-Jean - Hôpital Chicoutimi, Chicoutimi

H2W 1R7

Institut de Recherches Cliniques de Montréal, Montreal

H3G 1A4

Montreal General Hospital, Montreal

G1V 4T3

Diex Recherche Québec Inc., Québec

J1H 5N4

Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke

Sponsors
All Listed Sponsors
lead

Laurent Pharmaceuticals Inc.

INDUSTRY